Half of pregnant women starting HIV treatment developed raised blood pressure, whatever the regimen

Design

Secondary analysis of a three-arm randomised trial

Population

626 pregnant women with HIV, no baseline hypertension, randomised at 14–28 weeks

Primary outcome

Composite incident hypertension to 50 weeks postpartum

Effect

49% overall, no significant difference by arm; 8–17% higher hazard per 5 kg weight gain

This analysis of a randomised trial enrolled pregnant women with HIV at 14–28 weeks and assigned them to dolutegravir with emtricitabine and tenofovir alafenamide, dolutegravir with emtricitabine and tenofovir disoproxil fumarate, or efavirenz-based therapy, following them to 50 weeks postpartum. Among 626 women without hypertension at baseline (median age 26.6 years), the composite hypertension outcome occurred in 49%, mostly in the lowest 'elevated' band of 130–139/80–89 mmHg.

There was no significant difference between arms, though hypertension was numerically more frequent with dolutegravir. Each additional 5 kg of weight was associated with an 8–17% higher hazard of the composite outcome. Gestational hypertension was uncommon, at 4.3%, with no apparent difference by arm.

The practical point is weight rather than drug choice. Dolutegravir-based therapy is associated with weight gain, and weight gain here tracked blood pressure. Blood pressure and weight checks should continue after delivery, when antenatal visits stop.

• Measure blood pressure at every antenatal and postpartum HIV visit, not only at obstetric appointments
• Track weight change from the start of antiretroviral therapy
• Keep postpartum blood pressure checks going through the first year
• Do not switch away from dolutegravir on blood pressure grounds alone on this evidence

Why it matters

Raised blood pressure was common in young women with HIV after pregnancy, and it followed weight gain more than the drug.

Don't overread it

Hypertension was a secondary analysis the trial was not powered for, so a small difference between regimens cannot be excluded.

The statistics, in plain English

'No significant difference by arm' with a numerical excess means the trial could not rule out a small difference in either direction — it was not designed to answer this question. The 8–17% higher hazard per 5 kg is a within-arm association, so it describes who is at risk, not proof that weight causes the rise.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.